er-086526 and Adenocarcinoma--Scirrhous

er-086526 has been researched along with Adenocarcinoma--Scirrhous* in 1 studies

Other Studies

1 other study(ies) available for er-086526 and Adenocarcinoma--Scirrhous

ArticleYear
[A case of stage IV breast cancer successfully treated over 1 year with eribulin as fourth-line systemic chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:11

    A 59-year-old woman with an exudative, reddish bilateral breast tumor and dyspnea visited our hospital. She was diagnosed as having scirrhous carcinoma with metastasis to the liver and pleural effusion, designated as Stage IV, hormone receptor positive, and human epidermal growth factor receptor-2 (HER2) negative. Systemic chemotherapy (3 regimens) and endocrine therapy (5 regimens) were administered for a total of 5 years 7 months. Eribulin was administered as fourth line systemic chemotherapy. The pleural effusion reduced and dyspnea improved. Her status was maintained for 1 year 3 months. This case suggests that eribulin may provide long-term survival and maintenance of quality of life (QOL) in metastatic breast cancer patients.

    Topics: Adenocarcinoma, Scirrhous; Breast Neoplasms; Fatal Outcome; Female; Furans; Humans; Ketones; Middle Aged; Neoplasm Staging; Salvage Therapy

2014